Protalix BioTherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	76.38	52.74	53.4	65.49	47.64	38.35
Revenue Growth (YoY)	27.80%	-1.23%	-18.47%	37.48%	24.22%	-39.03%
Cost of Revenue	22.94	26.99	24.32	22.98	19.59	16.35
Gross Profit	53.44	25.75	29.08	42.51	28.05	22
Selling, General & Admin	12.13	11.68	12.19	14.96	11.71	12.73
Research & Development	21.52	19.57	12.97	17.09	29.35	29.73
Total Operating Expenses	33.65	31.25	25.16	32.05	41.06	42.46
Operating Income	19.79	-5.5	3.92	10.46	-13.01	-20.46
Interest Income	1.01	1.08	1.3	1.29	1.15	0.4
Interest Expense	-1.54	-1.19	-1.06	-3.18	-2.53	-7.52
Total Non-Operating Income (Expense)	-0.53	-0.11	0.24	-1.89	-1.38	-7.12
Pretax Income	19.27	-5.61	4.15	8.57	-14.4	-27.58
Provision for Income Taxes	1.94	-1	-1.22	-0.25	-0.53	-
Net Income	17.32	-4.61	5.38	8.82	-13.87	-27.58
Net Income to Common	15.33	-6.6	2.93	8.31	-14.93	-27.58
Net Income Growth	292.32%	-	-64.73%	-	-	-
Shares Outstanding (Basic)	79	79	73	68	48	44
Shares Outstanding (Diluted)	81	79	81	82	48	44
Shares Change (YoY)	-3.23%	-3.10%	-1.66%	70.04%	9.81%	51.43%
EPS (Basic)	0.19	-0.08	0.04	0.12	-0.31	-0.62
EPS (Diluted)	0.18	-0.08	0.04	0.09	-0.31	-0.62
EPS Growth	350.00%	-	-55.56%	-	-	-
Free Cash Flow	13	-13.63	7.39	-2.47	-25.63	-11.74
Free Cash Flow Per Share	0.16	-0.17	0.09	-0.03	-0.53	-0.27
Gross Margin	69.97%	48.82%	54.46%	64.91%	58.87%	57.37%
Operating Margin	25.91%	-10.43%	7.34%	15.97%	-27.32%	-53.36%
Profit Margin	22.68%	-8.74%	10.07%	13.47%	-29.11%	-71.92%
FCF Margin	17.02%	-25.84%	13.84%	-3.77%	-53.80%	-30.62%
EBITDA	21.31	-4.04	5.22	11.65	-11.93	-19.34
EBITDA Margin	27.90%	-7.65%	9.78%	17.79%	-25.04%	-50.44%
EBIT	19.79	-5.5	3.92	10.46	-13.01	-20.46
EBIT Margin	25.91%	-10.43%	7.34%	15.97%	-27.32%	-53.36%
Effective Tax Rate	10.08%	17.76%	-29.42%	-2.97%	3.68%	0.00%

SEC Filings: 10-K · 10-Q